Genetic Modification

What is Genetic Modification?

Genetic Modification (GM) is the process of altering an organism's DNA using biotechnology techniques to introduce desirable traits such as disease resistance, improved nutrition, or higher yields. It encompasses both transgenesis (inserting foreign genes from another species, e.g., Bt cotton) and genome editing (precise modification of existing genes using tools like CRISPR-Cas9, TALENs, or ZFNs). GM technology is applied across agriculture, medicine, industrial biotechnology, and environmental science.

In India, GM research and applications are regulated under the Rules for Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells, 1989, notified under the Environment (Protection) Act, 1986. The regulatory architecture involves multiple bodies: IBSC (Institutional Biosafety Committee), RCGM (Review Committee on Genetic Manipulation under DBT), and GEAC (Genetic Engineering Appraisal Committee under MoEFCC).

India's GM landscape is rapidly evolving with the 2022 exemption for SDN-1 and SDN-2 genome-edited plants from GM regulations, gene-edited rice trials showing 19% higher yields, and the launch of BIRSA-101 — India's first indigenous CRISPR-based gene therapy for sickle cell disease in November 2025.

How CRISPR-Cas9 Works

CRISPR-Cas9 acts as a molecular "scissors" for DNA. The system has two components: a guide RNA (gRNA) that is programmed to find a specific DNA sequence, and the Cas9 enzyme that cuts the DNA at that precise location. Once the DNA is cut, the cell's natural repair mechanisms either disable the gene (knockout) through error-prone Non-Homologous End Joining (NHEJ) or insert a desired sequence through Homology-Directed Repair (HDR). This makes CRISPR faster, cheaper, and more precise than older techniques like TALENs or ZFNs.

The SDN classification is critical for regulation: SDN-1 introduces small deletions/insertions without any foreign DNA (similar to natural mutations); SDN-2 uses a small template to make precise changes but no foreign gene; SDN-3 inserts a foreign gene, making it equivalent to traditional transgenesis. India's 2022 exemption covers only SDN-1 and SDN-2, treating them as conventional breeding techniques.

Key Features

Current Status / Latest Data

• SDN-1/SDN-2 Exemption (March 2022): MoEFCC exempted plants developed through SDN-1 and SDN-2 genome editing from GM regulations, as these do not involve foreign DNA insertion — a major policy shift aligning India with international practices.
• Gene-Edited Rice (2025): Two CRISPR-edited rice lines (from Samba Mahsuri and MTU-1010) completed multi-location trials showing ~19% higher yield and better tolerance to saline and alkaline soils.
• Gene-Edited Mustard: A low-pungency, fungal-resistant mustard line is under second-year trials and may be ready for release around 2026.
• BIRSA-101 (November 2025): India launched its first indigenous CRISPR-based gene therapy for sickle cell disease, specifically targeting tribal populations with high SCD prevalence.
• Regulatory Debate: While SDN-1/SDN-2 are exempted, SDN-3 (with foreign gene insertion) still requires full GEAC approval, maintaining a tiered regulatory approach.
• Global Context: India's exemption for genome-edited plants follows similar approaches by USA, Brazil, Argentina, Japan, and Australia.

UPSC Exam Corner

Prelims: Key Facts

• GM regulation in India: EPA 1986 + Rules 1989; apex body: GEAC (under MoEFCC)
• CRISPR-Cas9: Gene editing tool; Nobel Prize 2020 (Emmanuelle Charpentier & Jennifer Doudna)
• SDN-1 and SDN-2: Exempted from GM rules in India (March 2022 MoEFCC memorandum)
• Only approved GM crop in India: Bt cotton (since 2002)
• BIRSA-101: India's first CRISPR gene therapy for sickle cell disease (November 2025)
• RCGM: under DBT (Dept of Biotechnology); GEAC: under MoEFCC
• SDN-1: no foreign DNA (like natural mutation); SDN-2: template-directed; SDN-3: foreign gene
• CRISPR components: guide RNA + Cas9 enzyme; repair via NHEJ or HDR
• Gene-edited rice: 19% higher yield, saline-tolerant (multi-location trials 2023-24)
• Gene-edited mustard: low pungency, fungal resistant; release expected ~2026
• Global trend: USA, Brazil, Argentina, Japan, Australia also exempt SDN-1/SDN-2

Mains: Probable Themes

1. "Distinguish between transgenesis and genome editing. Why has India adopted a differential regulatory approach?"
2. "CRISPR technology has the potential to revolutionise agriculture and medicine in India. Discuss with examples."
3. "Examine the ethical, environmental, and socio-economic implications of genetic modification technology."
4. "India's 2022 exemption for genome-edited plants is a step towards science-based regulation. Critically analyse."
5. "Discuss the potential of gene therapy in addressing genetic disorders prevalent in India's tribal populations." — Link to BIRSA-101, sickle cell
6. "How does genome editing differ from traditional transgenesis? What are the regulatory implications of this distinction?"

Key Comparison: Transgenesis vs Genome Editing

• Transgenesis: Inserts foreign gene from another species; regulated as GMO globally; e.g., Bt cotton
• Genome Editing (SDN-1/SDN-2): Modifies existing genes without foreign DNA; increasingly exempted from GMO regulation; e.g., CRISPR rice, mustard

Sources: PRS India — Gene Editing Policy Brief | S&P Global — India Gene Editing Regulations | Nature — Gene-Edited Rice India | ForumIAS — Gene Modification to Genome Editing